argenx SE is a clinical‐stage biotechnology company focused on developing novel antibody therapies for severe autoimmune and inflammatory diseases. Headquartered in Ghent, Belgium, the company leverages its proprietary antibody engineering platform to identify and optimize biologics that modulate immune system targets with high specificity. argenx’s core mission is to bring breakthrough treatments to patients suffering from rare and debilitating conditions.
The company’s lead product, efgartigimod (commercialized under the brand name Vyvgart), is a first‐in‐class neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic IgG antibodies. Vyvgart has received regulatory approvals in several major markets, including indications for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Beyond Vyvgart, argenx maintains a diversified pipeline of preclinical and clinical candidates that address other immune‐mediated diseases such as immune thrombocytopenia and pemphigus vulgaris.
Founded in 2008 by a team of immunology experts, argenx has grown through strategic collaborations and in‐house research. Its proprietary platform enables rapid identification of antibody fragments with enhanced potency and functionality. Over the years, the company has established development partnerships with leading pharmaceutical firms to accelerate clinical programs and expand its geographic footprint.
Under the leadership of CEO Tim Van Hauwermeiren, argenx operates internationally with research and development hubs in Belgium, a U.S. presence in Boston, and commercial activities spanning North America, Europe and Asia. The company continues to invest in its pipeline and manufacturing capacity while exploring new therapeutic targets to address unmet needs in the autoimmune space.
AI Generated. May Contain Errors.
